Cargando…
Clinical significance of side population in ovarian cancer cells
Recently, accumulating evidence has suggested that tumors, including ovarian cancer, are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. The emergence of drug resistance is one of the most difficult problems in the...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051070/ https://www.ncbi.nlm.nih.gov/pubmed/21547690 http://dx.doi.org/10.1007/s13577-010-0002-z |
_version_ | 1782199433686941696 |
---|---|
author | Hosonuma, Shinji Kobayashi, Yoichi Kojo, Satoshi Wada, Haruka Seino, Ken-ichiro Kiguchi, Kazushige Ishizuka, Bunpei |
author_facet | Hosonuma, Shinji Kobayashi, Yoichi Kojo, Satoshi Wada, Haruka Seino, Ken-ichiro Kiguchi, Kazushige Ishizuka, Bunpei |
author_sort | Hosonuma, Shinji |
collection | PubMed |
description | Recently, accumulating evidence has suggested that tumors, including ovarian cancer, are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. The emergence of drug resistance is one of the most difficult problems in the treatment of ovarian cancer, which has been explained recently by the potential of CSCs to have superior resistance against anti-cancer drugs than conventional cancer cells. In this study, we expanded this line of study to examine whether this phenomenon is also observed in clinical specimens of ovarian cancer cells. In total we could analyze 28 samples out of 60 obtained from ovarian cancer patients. The clinical samples were subjected to testing of the expression of side population (SP) as a CSC marker, and according to the presence of SP (SP+) or absence of SP (SP−), clinicopathological significances were analyzed. Although there was no statistical significance, there were more SP+s in recurrent cases as well as in ascitic and peritoneal dissemination than in primary tumor of the ovary. There was no correlation between SP status and FIGO staging. In 19 cases of those who could be followed more than 6 months from initial therapy, there were 8 cases of recurrence or death from disease, and all of these were SP+. On the other hand, in 11 cases of disease-free survivors, 6 were SP+. There was a significant difference in prognosis between SP+ and SP− (p = 0.017). Although this study was limited, it revealed that SP could be contained more in recurrent or metastatic tumors than in primary tumors, and also that the presence of SP could be a risk factor of recurrence in ovarian cancer. Therefore, a novel therapeutic strategy targeting SP could improve the prognosis of ovarian cancer. |
format | Text |
id | pubmed-3051070 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-30510702011-04-05 Clinical significance of side population in ovarian cancer cells Hosonuma, Shinji Kobayashi, Yoichi Kojo, Satoshi Wada, Haruka Seino, Ken-ichiro Kiguchi, Kazushige Ishizuka, Bunpei Hum Cell Research Article Recently, accumulating evidence has suggested that tumors, including ovarian cancer, are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. The emergence of drug resistance is one of the most difficult problems in the treatment of ovarian cancer, which has been explained recently by the potential of CSCs to have superior resistance against anti-cancer drugs than conventional cancer cells. In this study, we expanded this line of study to examine whether this phenomenon is also observed in clinical specimens of ovarian cancer cells. In total we could analyze 28 samples out of 60 obtained from ovarian cancer patients. The clinical samples were subjected to testing of the expression of side population (SP) as a CSC marker, and according to the presence of SP (SP+) or absence of SP (SP−), clinicopathological significances were analyzed. Although there was no statistical significance, there were more SP+s in recurrent cases as well as in ascitic and peritoneal dissemination than in primary tumor of the ovary. There was no correlation between SP status and FIGO staging. In 19 cases of those who could be followed more than 6 months from initial therapy, there were 8 cases of recurrence or death from disease, and all of these were SP+. On the other hand, in 11 cases of disease-free survivors, 6 were SP+. There was a significant difference in prognosis between SP+ and SP− (p = 0.017). Although this study was limited, it revealed that SP could be contained more in recurrent or metastatic tumors than in primary tumors, and also that the presence of SP could be a risk factor of recurrence in ovarian cancer. Therefore, a novel therapeutic strategy targeting SP could improve the prognosis of ovarian cancer. Springer Japan 2011-01-07 2011 /pmc/articles/PMC3051070/ /pubmed/21547690 http://dx.doi.org/10.1007/s13577-010-0002-z Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Research Article Hosonuma, Shinji Kobayashi, Yoichi Kojo, Satoshi Wada, Haruka Seino, Ken-ichiro Kiguchi, Kazushige Ishizuka, Bunpei Clinical significance of side population in ovarian cancer cells |
title | Clinical significance of side population in ovarian cancer cells |
title_full | Clinical significance of side population in ovarian cancer cells |
title_fullStr | Clinical significance of side population in ovarian cancer cells |
title_full_unstemmed | Clinical significance of side population in ovarian cancer cells |
title_short | Clinical significance of side population in ovarian cancer cells |
title_sort | clinical significance of side population in ovarian cancer cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051070/ https://www.ncbi.nlm.nih.gov/pubmed/21547690 http://dx.doi.org/10.1007/s13577-010-0002-z |
work_keys_str_mv | AT hosonumashinji clinicalsignificanceofsidepopulationinovariancancercells AT kobayashiyoichi clinicalsignificanceofsidepopulationinovariancancercells AT kojosatoshi clinicalsignificanceofsidepopulationinovariancancercells AT wadaharuka clinicalsignificanceofsidepopulationinovariancancercells AT seinokenichiro clinicalsignificanceofsidepopulationinovariancancercells AT kiguchikazushige clinicalsignificanceofsidepopulationinovariancancercells AT ishizukabunpei clinicalsignificanceofsidepopulationinovariancancercells |